First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2013-12-03 09:36:33Open Document File Size: 278,64 KBShare Result on FacebookCompanyPluristem Therapeutics Inc. / United Therapeutics / Needham / Biotechnology & Life Sciences Pluristem Therapeutics Inc. / Needham & Company LLC / Options Clearing Corporation / /CountryUnited States / /CurrencyUSD / / /EventFDA Phase / Business Partnership / /IndustryTermbiopharmaceutical / grade product / banking / 3D cell culture technology / manufacturing capabilities / /MedicalConditionintermittent claudication / muscle injury / burn / degenerative diseases / Buerger's disease / Buerger’s disease / Pulmonary Hypertension / inflammatory / /MedicalTreatmentstem cell therapy / cell therapy / /OperatingSystemPluriX / /OrganizationFDA / European Union / FINRA / /PersonBryan Huang / Mark Monane / / /Positionauthor / advisor / board member / officer / director / sales representative / analyst / analyst and research associate / sales representative for specific guidance / research associate / Jun ANALYST / /Product4Q11 / PLX-PAD / /ProvinceOrStateNew York / /Technology3D cell culture technology / cell therapy / regenerative medicine / /URLhttp /SocialTag |